Patients with a history of venous thrombotic episodes such as deep venous thrombosis, pulmonary embolus occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy; similarly, patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy
Subjects with a history of venous thrombosis within the past 3 months
Patients with a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to registration
History of unprovoked venous thrombosis/thromboembolism
History of venous thromboembolism (e.g. deep venous thrombosis or pulmonary embolism) within 6 months of study entry; Note: participants enrolled after this window must be on appropriate therapeutic anticoagulation
History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port of catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to enrollment
Active venous thrombosis with contraindication for anticoagulation
Requirement of therapeutic anticoagulant therapy with oral vitamin K antagonists; low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed; therapeutic use of low molecular weight heparin (or similar parenteral drug) for venous-thromboembolic disease is allowed
Patients determined to be at increased risk of arterial or venous thrombosis by the investigator
History of deep venous thrombosis, clinically significant peripheral vascular disease, or other thrombotic event
Has a history of arterial thromboembolism within 12 months of start of study drug
Internal jugular venous thrombosis, acute or within 3 months.
Any history of venous or arterial thromboembolism including deep venous thrombosis or pulmonary embolism. Patients with a history of treated prior superficial or catheter associated will not be considered as significant embolism and after discussion with principal investigator (PI) will not be excluded from eligibility. Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
Subject has a history of non-central line related thrombosis (arterial or venous), more than one prior central-line related thrombosis or known coagulopathy.
PONATINIB \r\n* Patients with cytogenetically ‘favorable risk' AML (core-binding factor leukemias) will not be enrolled on the ponatinib arm; testing with cytogenetics and fluorescence in situ hybridization (FISH) can establish this subtype within 7 days of the diagnostic bone marrow biopsy\r\n* History of acute pancreatitis within 1 year of study or history of chronic pancreatitis\r\n* Uncontrolled hypertriglyceridemia (triglycerides > 450 mg/dL)\r\n* Any history of myocardial infarction, stroke, or revascularization\r\n** Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism with the exception of upper Extremity/Line associated deep vein thrombosis (DVTs) which are adequately treated (line removed and/or patient anti-coagulated)\r\n* Uncontrolled hypertension (diastolic blood pressure > 90 mm Hg; systolic > 140 mm Hg); patients with hypertension should be under treatment on study entry to effect blood pressure control
Patients with history of bleeding diathesis, arterial thromboembolism, current use of therapeutic anticoagulation with oral vitamin K antagonists, factor Xa inhibitors, heparin products, oral direct thrombin inhibitors, or presence of non-healing wounds; low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed
The patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to randomization
History of arterial thrombosis within 3 months of starting study treatment
The patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism, including portal venous thrombosis (venous port or catheter thrombosis, incidental pulmonary embolism diagnosed on imaging studies or superficial venous thrombosis are not considered significant) during the 3 months prior to randomization
Has had a symptomatic venous thrombosis within 2 weeks prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis >2 weeks prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study
Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment
Patients with history of recurrent venous thromboembolism (deep venous thrombosis or pulmonary embolism) or history of venous thromboembolism within 6 months prior to registration on study will not be eligible
History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to randomization
Patients must not have been previously diagnosed with a deep venous or arterial thrombosis (including pulmonary embolism), and must not have a known thrombophilic condition
MATCHED RELATED DONOR: Other medical contraindications to stem cell donation (i.e. severe atherosclerosis, autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular accident)
Patients with a history of arterial or venous thrombosis
Patients with history of deep venous thrombus or pulmonary embolism. Patients who are at increased risk of thrombosis during treatment with lenalidomide including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also excluded.
History of venous or arterial thrombosis within the preceding year of enrollment
Have had DVT or venous thromboembolism within 6 weeks of study entry
Patients with a history of idiopathic deep venous thrombosis, pulmonary embolus, thrombotic stroke, or arterial thrombosis will be excluded from study; patients with a history of a central venous catheter-associated thrombosis that has completely resolved will be eligible for study but should be monitored for thrombosis
Patients at high-risk for thromboembolic disease, such as those with prior heterotopic ossification (h/o) deep venous thrombosis (DVT).
Patients with history of clinically significant venous thromboembolism
Patients with a history of clinically significant venous thromboembolism will be excluded
Patients with a history of venous or arterial thrombosis personally before the age of 40 years unless associated with a central line
Has had a symptomatic venous thrombosis within the 14 days prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis 14 days prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study
They have a history of a venous or arterial thrombosis that was not associated to a central line.
The patient has a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \significant\) during the 3 months prior to first dose of protocol therapy
Patient must have no history of venous thrombosis within 12 weeks of randomization
History of clinically significant hemorrhagic or thrombotic event within the past 6 months, not including uncomplicated catheter-associated venous thrombosis; patients on anti-coagulation are not permitted to be on any oral formulations (warfarin, rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction
History of untreated deep venous thrombosis
have a history of deep venous thrombosis/embolism and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
Have a history of arterial or venous embolism within 6 months prior to study entry.
Surgical arterial-portal venous shunt or arterial-venous shunt
Have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism (venous catheter thrombosis or superficial venous thrombosis not considered \significant\) during the 3 months prior to study enrollment. Participants with venous thromboembolism occurring 3 to 6 months prior to study enrollment are allowed, if being treated with low molecular weight heparin.
History of deep venous thrombosis or migratory thrombophlebitis (Trousseau)
Subjects who are unwilling to take venous thromboembolism (VTE) prophylaxis
The participant has a history of arterial thromboembolism event (ATE) or venous thromboembolism event (VTE) within 3 months prior to study enrollment. Participants with history of VTE beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.
History of recurrent thrombosis or any thrombosis within the past 6 months
Has a history of arterial thromboembolism within 12 months of start of study drug
Patients with a history of deep venous thromboembolism or pulmonary embolism on treatment with anticoagulation are eligible for the study
History of arterial thrombosis (i.e. stroke) in the past year
History of venous thrombosis currently requiring anti-coagulation therapy
The patient has a known history of stroke, myocardial infarction, peripheral vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis.
PART B: Any history of venous or arterial thrombo-embolism, or previous revascularization procedure
History of arterial thrombosis (i.e. stroke) in the past year
History of venous thrombosis currently requiring anti-coagulation therapy
The ability to take aspirin or other appropriate venous thromboembolism (VTE) prophylaxis
History of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
Patients with history of deep venous thrombus or pulmonary embolism; patients who are at increased risk of thrombosis during treatment with Revlimid including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also excluded
Patients must not have had a deep venous or arterial thrombosis (non-central venous catheter related) within the last three months prior to study entry
Patients known or suspected to have hypercoagulable syndrome or with history of venous or arterial thrombosis, stroke, transient ischemic attack (TIA), or pulmonary embolism
Documented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the study
History of deep venous or arterial thrombotic disease (including but not limited to, acute myocardial infarction due to coronary thrombosis, ischemic stroke, and peripheral arterial disease), unless:\r\n* Line-related thrombosis without embolus\r\n* Occurring >= 1 year prior to screening
Venous thromboembolism within one year
Venous thromboembolism within one year
Patients with a history of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently requiring systemic anticoagulation are eligible provided they are determined to be candidates for radical prostatectomy
History of arterial or venous embolism within 3 months prior to study enrollment. If the embolism occurred >3 and <6 months, the participant is eligible provided appropriate treatment according to institutional standard of care is ensured.
Significant or active cardiovascular disease, specifically including but not restricted to:\r\n* History of myocardial infarction \r\n* History of atrial or ventricular arrhythmia\r\n* Unstable angina within 6 months prior to first dose of ponatinib\r\n* History of congestive heart failure \r\n* Left ventricular ejection fraction (LVEF) less than lower limit of normal \r\n* History of peripheral arterial occlusive disease \r\n* History of cerebrovascular accident or transient ischemic attack \r\n* Venous thromboembolism including deep venous thrombosis or pulmonary embolism within 6 months prior to enrollment
History of arterial or deep venous thromboembolism within the 12 months prior to enrollment
Documented deep venous thrombosis
Clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screening
Patients with a history of venous or arterial thrombosis personally or in a first degree relative before the age of 40 years are not eligible unless the thrombotic event was associated with a central line.
Known arterial or venous thrombosis or pulmonary embolism within 2 years
History of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
Patients with a history of clinically significant venous thromboembolism will be excluded on cohort 2; patients with tumor associated thrombus in the renal vein will not be excluded
DONOR: No other medical contraindications to stem cell donation (i.e. severe atherosclerosis, autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular accident); patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis
Absolute contraindications: venous injury at the level of the femoral veins or proximally; known or suspected thrombosis of the femoral or iliac veins on the proposed side of venous cannulation, ambulatory patient
Patients with a history of the arterial or venous thromboembolism within =< 12 months of study entry are not eligible
History of arterial or venous thrombosis (excluding line-thrombosis) within the last 1 year, or those with known inherited coagulopathies; arterial or venous thrombosis includes pulmonary embolism, deep vein thrombosis of both upper (excluding line-thrombosis) and lower extremities, coronary artery disease managed medically or requiring intervention (percutaneous stent placement or coronary bypass surgery), cerebrovascular accident (for transient ischemic attacks clinical documentation is required), or involvement of other organs (such as hepatic, renal, spleen or other sites)
Arterial or venous thrombosis in the last year except for line-related venous thrombosis more than 3 months ago
Separate episode of VTE or arterial thrombosis within 3 months of enrollment
History of a deep venous thrombosis or a thromboembolism
Patients with a history of a prior symptomatic venous thrombotic event, such as deep venous thrombosis (DVT) or pulmonary embolism and symptomatic arterial thrombotic events such as myocardial infarction, ischemic cerebral vascular accident or transient ischemic attack will be ineligible if they have not tolerated anticoagulation therapy; if patients remain on anticoagulation, or have completed the prescribed course of anticoagulation, they will be eligible for enrollment; a venous thrombotic event associated with a central venous catheter will not make the patient ineligible
Patients with existing deep venous thrombosis will be excluded
Medical conditions:\r\n* Have a predisposition to or prior history of thromboembolism, deep venous thrombosis, pulmonary embolism, or stroke\r\n* History of renal or liver disease\r\n* Prior ovarian or endometrial cancer\r\n* Stopped or started hormone replacement within 8 weeks\r\n* Any other condition or intercurrent illness that in the opinion of the investigator makes the woman a poor candidate for RPFNA.
Arterial or venous thrombosis requiring active anticoagulation; (if a patient has a history of arterial or venous thrombosis and has completed anticoagulation therapy, then he/she is not excluded)
Patients who have a history of venous or arterial thromboembolic events including pulmonary embolism, deep venous thrombosis and stroke
Subjects with stroke, arterial or venous thrombosis within 6 months not eligible
Active deep venous thrombosis, pulmonary embolism, retinal vascular thrombosis, and any arterial thrombosis including stroke and myocardial infarction or history of these conditions
Patients with current deep vein thrombosis or deep vein thrombosis within the past 6 months are not eligible
STEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
Patients will be excluded if any of the following are present:\r\n* Evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis\r\n* History (within 6 months prior to study enrollment) of pulmonary embolism, deep vein thrombosis (DVT), or other venous thromboembolic event\r\n* History of hemoptysis within 6 weeks prior to study enrollment
History of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or untreated DVT (deep vein thrombosis)
Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or are currently receiving therapeutic or prophylactic doses of anticoagulants.
Participants with history of pulmonary embolism, deep vein thrombosis (DVT), or vascular access related thrombosis will be allowed on study provided they are receiving adequate anticoagulation at a stable dose at the time of study entry
Presence of deep vein thrombosis based on screening lower extremity Doppler ultrasonography.
History of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for 2 weeks).
History of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 6 months
Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment
Deep vein thrombosis or pulmonary embolism =< 4 weeks before first dose of protocol-indicated treatment, unless adequately treated and stable.\r\n* Patients receiving therapeutic non-coumarin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulant.
A diagnosis of deep vein thromboses in the preceding four weeks of study enrollment.
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
Deep vein thrombosis (DVT) / pulmonary embolism (PE) in the past 6 months prior to randomization
Thrombotic events (pulmonary embolism; deep venous thrombosis) within 6 month prior to start of therapy
Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).
Thromboembolic events and/or bleeding disorders ? 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug
Patients unwilling to take deep vein thrombosis (DVT) prophylaxis.
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
If prior history of deep vein thrombosis (DVT)/pulmonary embolism (PE), the patient needs to be on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeks
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
History or presence within the last 3 months of Deep Vein Thrombosis (DVT) or a pulmonary embolism (PE);- Uncontrolled leptomeningeal disease;
have a history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism or retinal vein thrombosis, unless currently on anticoagulant therapy;
Subject has active or history of deep vein thrombosis (DVT)
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment
Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ? 4 weeks of C1D1.
Prior or concurrent deep vein thrombosis or pulmonary embolism
History of arterial thrombosis; patients with history of deep vein thrombosis (DVT) are eligible as long as they have received or are receiving appropriate anticoagulation therapy
Patients with documented deep venous thrombosis or pulmonary embolism within the past 3 months
History of deep vein thrombosis or pulmonary embolism within 6 month of anticipated starting of axitinib
Concurrent medical problems that preclude use of deep vein thrombosis (DVT) prophylaxis with lenalidomide treatment
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of\r\nstudy enrollment)
Myocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous 6 months; subjects with a history of deep vein thrombosis or pulmonary embolism, at provider discretion
Subjects with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 6 months of study treatment initiation
Any of the following in the previous 6 months: deep vein thrombosis or symptomatic pulmonary embolism
History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
significant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure, ongoing arrhythmias of Grade > 2 , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
History of deep venous thrombosis and pulmonary embolism (Phase 1b).
History of deep venous thrombosis (DVT) or pulmonary embolism (PE)
Recent venous thrombosis within 4 weeks prior to study registration; patients at high risk for thrombotic events due to inherited risk factors (i.e. factor V Leiden) or deep vein thrombosis (DVT)/pulmonary embolism (PE) in the past 12 months should be on secondary prophylaxis with anti-coagulant therapy (i.e. warfarin or low molecular weight heparin) prior to enrollment
Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to initiate prophylaxis with low molecular weight heparin
Deep vein thrombosis or pulmonary embolism within 3 months of study entry
History of deep vein thrombosis and/or pulmonary embolism within 4 weeks of enrollment.
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.
Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulation
Deep vein thrombosis or pulmonary embolism =< 4 weeks before first dose of protocol-indicated treatment, unless adequately treated and stable
History of unprovoked deep vein thrombosis/pulmonary embolism (DVT/PE) in past twelve (12) months
History of vascular disease (e.g. deep vein thrombosis, stroke)
Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first IMP administration.
Patients with any prior history of arterial thrombosis or symptomatic pulmonary embolism
Patients must not have a history of prior stroke, transient ischemic attack (TIA), pulmonary embolism, or untreated deep vein thrombosis\r\n* NOTE: Patients may be eligible if they have received at least 3 months of anticoagulation for a deep vein thrombosis
History of deep vein thrombosis or pulmonary embolism within 6 months of screening; patients who are currently taking anticoagulation therapy for a prior history (> 6 months from screening) of thrombosis may still be eligible
History of blood clots, pulmonary embolism, or deep vein thrombosis in previous 6 months unless controlled by anticoagulant treatment
Prior history of a major thrombotic event, such as pulmonary emboli, deep vein thrombosis or stroke, as assessed by the investigator, or history of an asparaginase associated serious hemorrhage or thrombus requiring anticoagulation therapy
Any history of a venous thromboembolic event (VTE), including deep vein thrombosis\n             (DVT) or pulmonary embolism (PE)
Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
History of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or untreated DVT (deep vein thrombosis)
Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation.
History of thromboembolic events and/or bleeding disorders ? 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug
Has a history of deep vein thrombosis or pulmonary embolism within 6 months of screening.
Absence of history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia; patients with a history of deep vein thrombosis(DVT)/pulmonary embolism (PE) or thrombophilia may participate if they are willing to be on full anticoagulation during the treatment if randomized to rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R2CHOP) arm A; full anticoagulation is defined as warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses
Has had a deep venous thrombosis (DVT) or pulmonary embolism within the 3 months prior to study enrollment. NOTE: Subjects with a history of a DVT or pulmonary embolism >3 months prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study.
Patients with the following: \r\n* Bleeding diathesis or patients in whom prophylactic antithrombotic therapy is otherwise contraindicated \r\n* Patients with prior deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thromboembolism \r\n* Patients with ischemic stroke or transient ischemic attack (TIA)
Participants with prior history of thromboembolic disease (i.e. deep venous thrombosis [DVT] or pulmonary embolism [PE] within the last six months)
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
Known, existing uncontrolled coagulopathy; patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade 2 or greater bleeding episode in the 3 weeks before day 1
Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment (patient must be on stable dose for 2 weeks).
Deep vein thrombosis (DVT)/pulmonary embolism (PE) in the past 6 months
History of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment.
Have had a new pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment (any thrombosis within 2 months of study enrollment must be approved by the protocol chair and/or medical monitor)
Patients with prior deep vein thrombosis (DVT) or pulmonary embolism (PE) currently on anticoagulation regimen will be permitted
History of thromboembolic events (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) ? 2 weeks before the first dose of study drug and/or clinical diffuse intravascular coagulation (DIC)
In past 6 months: deep vein thrombosis or pulmonary embolism
Evidence of deep vein thrombosis (DVT) or pulmonary embolism (PE) or other known thromboembolic event present during screening period.
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment)
Subjects with deep vein thrombosis (DVT) and Pulmonary embolism (PE) within 3 months prior to day 1 treatment
Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) within 6 months of screening
Candidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic anticoagulation, if otherwise deemed to be suitable for RP
Patient at high risk for deep vein thrombosis not willing to take DVT prophylaxis.
History of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 months
History of pulmonary embolism or deep venous thrombosis within the past six months of the first dose of study treatment
The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin or sudden cardiac arrest. Any participant with a history of venous thromboembolism (VTE) (for example, deep vein thrombosis [DVT] of the leg or arm and/or pulmonary embolism) will be excluded.
Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months prior to enrollment.
Deep vein thrombosis in the preceding 2 months.
Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event =< 30 days before enrollment
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment)
No prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study
Pulmonary embolism, deep vein thrombosis, or other significant venous event =< 8 weeks before enrollment
Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (CTC Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), a second active malignancy (excluding basal cell carcinoma and cervical carcinoma in situ), organ transplantation.
History of deep venous thromboses or pulmonary embolism =< 365 days prior to registration
Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.
Occurrence of deep vein thrombosis within 4 weeks, prior to study entry
Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening
Deep vein thrombosis diagnosed within 3 months
History within 3 months of deep vein thrombosis, pulmonary embolism, or stroke
Diagnosed active deep vein thrombosis (DVT) that has not been therapeutically anticoagulated
History of thromboembolic events and bleeding disorders ?3 months (e.g., (deep vein thrombosis) DVT or pulmonary embolism (PE))
Patients with a history of deep vein thrombosis or thromboembolism within < 6 months prior to starting study treatment
Prior or concurrent deep vein thrombosis or pulmonary embolism
No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.
History of deep vein thrombosis or pulmonary embolism.
Patients with a history of deep vein thrombosis or thromboembolism within < 6 months prior to starting study treatment
History of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) =< 180 days
Patients must not have a prior history of deep vein thrombosis (DVT) or pulmonary embolism in the past 5 years
Suspected or diagnosed deep vein thrombosis or painful foot neuropathy.
Active deep vein thrombosis in the treatment extremity
History of deep vein thrombosis (DVT) in the lymphedematous upper extremity
History of deep venous thrombosis or embolic event (eg, pulmonary embolism) within 6 months prior to randomization.
History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke AND have not been stable on anticoagulants within the past 6 months; local central line thrombosis is allowed
Ongoing use or planned peri-operative use of anticoagulants (not including deep vein thrombosis [DVT] prophylaxis)
Known history of VTE prior to diagnosis (deep vein thrombosis [DVT] or pulmonary embolism PE) due to increased underlying risk of new event
History of blood clots (i.e. pulmonary embolism, deep vein thrombosis [DVTs])
History of deep vein thrombosis or pulmonary embolism within 4 weeks of first study dose
Patients with thrombosis within the splenic vein
Symptomatic deep vein thrombosis or pulmonary embolism within last 6 months
No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of starting IFN gamma
Patients who will require anticoagulant medications other than routine deep vein thrombosis (DVT) prophylaxis within 8 days postoperatively
History of deep vein thrombosis or pulmonary embolism.
Participants requires the use of warfarin (use in prophylactic doses [example, deep vein thrombosis prophylaxis]) is allowed.
History of deep vein thrombosis and/or pulmonary embolus within 3 months of study entry
Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
Deep vein thrombosis (DVT) or pulmonary embolus which require use of oral anticoagulants or, if on low molecular weight heparin, have not been on a stable dose for at least 2 weeks
Patients who have a history of deep vein thrombosis or pulmonary embolus and are stable on anticoagulation for > 1 month are eligible
Patients with a recent history of deep vein thrombosis or pulmonary embolus, in the six months prior to enrollment are not eligible for this study
Patients with any of the following within 6 months of enrollment: deep vein thrombosis, pulmonary embolus, myocardial infarction, cerebrovascular accident, unexplained loss of consciousness
Patients being treated with full dose warfarin are excluded. Patients with history of deep vein thrombosis or pulmonary embolus who are being treated with therapeutic doses of low molecular weight heparin or prophylactic dose anticoagulants may be enrolled.
History of pulmonary embolus and/or substantial deep vein thrombosis
History of documented pulmonary embolus within 6 months of enrollment
Conditions contraindicated to progesterone treatment (including, but not limited to, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke, allergy to peanuts, hypersensitive to progesterone and liver dysfunction)
Known history of deep vein thrombosis or pulmonary embolus except in patients where the cause was directly related to foreign body implants, i.e. central venous catheters, portacaths, etc.
History or clinical evidence of deep venous thrombosis including pulmonary embolus within 6 months of treatment
Cerebrovascular accident or pulmonary embolus within 3 months of randomization.
Pulmonary embolus or thrombosis of the deep venous system (deep vein thrombosis [DVT]) within 2 weeks of starting study treatment; patients who had a history of thromboembolic disease should be stable on therapeutic anticoagulation using low molecular weight (LMW) heparin for at least 2 weeks prior to the start of study treatment; use of warfarin (or derivatives) is not allowed at the start of study treatment
Patients who have had a deep vein thrombosis or pulmonary embolus within the past 6 months are eligible if they are on stable therapeutic anticoagulation
Patients with a recent history of deep vein thrombosis (DVT) or pulmonary embolus (PE), in six months prior to enrollment are not eligible for this study
Within the past 6 months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosis
CONTROL (HEALTHY) GROUP: Within the past 6 months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosis
History of: Thrombophelitis, Deep vein thrombosis, Pulmonary embolus, Clotting disorder, Bleeding disorder, Heart disease, Diabetes, Stroke, Peanut allergy, Liver dysfunction, Hypersensitivity to progesterone
Patients with a history of any one or more of the following thromboembolic events within the past 6 months prior to study enrollment are NOT eligible for participation: \r\n* Pulmonary embolism\r\n* Untreated deep venous thrombosis (DVT)\r\n** Subjects with recent DVT who have been therapeutically coagulated for at least 6 weeks ARE eligible
Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months\r\n* Note: subjects with recent DVT who have been therapeutically coagulated for at least 6 weeks are eligible
History of a major thromboembolic event =< 6 months prior to randomization, including cerebrovascular accident, transient ischemic attack (TIA), myocardial infarction, symptomatic pulmonary embolism (PE) or untreated deep venous thrombosis (DVT), or coronary artery bypass graft surgery; NOTE: Subjects with recent DVT or asymptomatic PE who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months
Any of the following conditions =< 6 months prior to registration:\r\n* Cerebrovascular accident (CVA) or transient ischemic attack (TIA)\r\n* Serious or unstable cardiac arrhythmia\r\n* Admission for unstable angina or myocardial infarction\r\n* Cardiac angioplasty or stenting\r\n* Coronary artery bypass graft surgery\r\n* Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation =< 30 days\r\n* Arterial thrombosis\r\n* Symptomatic peripheral vascular disease
Cerebrovascular accident at any time in the past, transient ischemic attack, deep venous thrombosis or pulmonary embolism in the past 6 months
History of cerebrovascular accident including transient ischemic attack, pulmonary embolism (including asymptomatic or previously treated pulmonary embolism [PE]), or untreated deep venous thrombosis within the past 6 months; patients with recent deep vein thrombosis (DVT) who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), myocardial infarction, pulmonary embolism or untreated deep venous thrombosis (DVT), coronary artery bypass graft surgery within 6 months prior to registration; Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months; Note: Participants with recent DVT who have been treated with therapeutic anti-coagulants for at least 6 weeks are eligible, with the exception of participants being treated with warfarin, which is prohibited on this study; other oral anti-coagulants may be allowed after discussion with overall principle investigator (PI), but short half-life low molecular weight heparins are strongly preferred
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: patients with recent DVT who have been treated with therapeutic anticoagulation agents for at least 6 weeks are eligible as long as their INR is stable and within inclusion criteria above
History of cerebrovascular accident including transient ischemic attack, pulmonary embolism (PE) (including asymptomatic or previously treated PE), or untreated deep venous thrombosis within the past 6 months; patients with deep venous thrombosis (DVT) who are being treated with therapeutic anti-coagulating agents are eligible
Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past 6 months. Deep venous thrombosis within 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred.
Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past 6 months. Deep venous thrombosis within 6 months unless the patient is anticoagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred.
History of stroke, deep venous thrombosis (DVT), or transient ischemic attack (TIA)
Previous history of cerebrovascular accident (CVA), transient ischemic attack (TIA), angina pectoris, acute myocardial infarction (MI) or history of recent re-perfusion procedures (e.g. percutaneous transluminal coronary angioplasty [PTCA]), pulmonary embolus or untreated deep vein thrombosis (DVT) within 6 months from day 1 of study drug; NOTE: subjects with recent DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks prior to study treatment are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
Patient must not have a history of cerebrovascular accident including transient ischemic attack within the past 6 months; patients with recent deep venous thrombosis or pulmonary embolism who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible as long as INR is stable
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within 6 months of registration; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks prior to registration and are fully anti-coagulated are eligible
History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: Patients with recent DVT who have been treated with therapeutic anticoagulation including Coumadin or any low molecular weight heparin for at least 6 weeks are eligible
History of cerebrovascular accident (CVA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack, untreated deep venous thrombosis (DVT) or pulmonary embolism within the past 6 months; patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible but must be monitored regularly for changes in relevant coagulation parameters as clinically indicated as well as any clinical bleeding episodes
History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
EXPANSION COHORT ONLY: History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
History of cerebrovascular accident including transient ischemic attack, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months.
History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
Deep venous thrombosis (DVT) diagnosed within 12 months of study enrollment or history or untreated lower extremity DVT, bone metastases, currently active skin infection, or lymphedema currently involving the treatment field
Patient must not have history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months\r\n* Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible